The problem
Awakened Grains holds a patent — U.S. Patent No. 2018215090 — on controlled grain germination: the CERES-MNG™ process behind a functional flour sold to enterprise food manufacturers. Selling a novel ingredient to an enterprise R&D bench is a credibility problem before it is a sales problem: the buyer is a scientist with a procurement officer behind them, and both are paid to disbelieve.
The client had the evidence — a patent, lab-verified nutrition data. What it lacked was the evidence assembled in the order an enterprise buyer actually evaluates.
The build
Lotus built the site as an evidence sequence: patent grounding, lab-verified data, and regulatory-claim literacy before any commercial ask. Nine production pages carry the argument, and the numbers in the data layer are the lab’s, not the copywriter’s — Eurofins-verified deltas against conventional flour of +128% protein, +1,193% fiber, −29% calories, −61% net carbs.
The centerpiece treats regulation as arithmetic: a working ROI calculator checks a manufacturer’s blend against the real FDA “excellent source of fiber” threshold — 5.6g per 100g, 20% of Daily Value — encoded as executable logic, so a prospect learns on the page whether a reformulation earns the label claim. The build is a static site by design and honest about its stage: lead capture goes live when the client configures the endpoint.
What it proves
A claim a buyer reads is marketing; a claim a buyer can test is enablement. The narrative capability at this firm ships the second kind — the FDA threshold is in the code, where a skeptic can run it.